Myelosuppression Behandling med Tasigna er associeret med (National Cancer Institute Common Toxicity Criteria grad 3- 4) trombocytopeni, neutropeni og anæmi.
Myelosuppression Treatment with Tasigna is associated with (National Cancer Institute Common Toxicity Criteria grade 3-4) thrombocytopenia, neutropenia and anaemia.